Extended survival in patients with relapsed myeloma confirmed in Phase III trial results of Velcade

Published: 2004-09-17 06:57:00

Updated: 2004-09-17 06:57:00

In the final survival endpoint analysis in the Phase III confirmatory APEX study comparing patients receiving Velcade (bortezomib) injection to those receiving high-dose dexamethasone, Velcade produced a statistically significant survival benefit, said an official at Janssen Korea. Recently, the ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK